🔊CEOInterviews

Karen Akinsanya on AI/ML

From Schrodinger's Karen Akinsanya on NewYorkBIO's #VirtualBreakfast webinar series · · NewYorkBIO Video Channel

“AI and machine learning are very good at working with large training sets, but when you're working on a protein without existing molecules in the dataset, these models struggle. That's why we start with physics-based methods and then use ML to sort through results, combining the strengths of both approaches.”

Karen Akinsanya
President of Research & Development Therapeutics, SCHRODINGER INC
AI/MLdrug discoverycomputational chemistry

On , Karen Akinsanya, President of Research & Development Therapeutics at SCHRODINGER INC, spoke about AI/ML during Schrodinger's Karen Akinsanya on NewYorkBIO's #VirtualBreakfast webinar series on NewYorkBIO Video Channel.

Schrodinger's Karen Akinsanya  on NewYorkBIO's #VirtualBreakfast webinar series
Watch on YouTube
Schrodinger's Karen Akinsanya on NewYorkBIO's #VirtualBreakfast webinar series
NewYorkBIO Video Channel
Watch on YouTube
NewYorkBIO's breakfast series has gone virtual! Providing engaging speakers on innovation, clinical development, patient ...
Karen Akinsanya

About Karen Akinsanya

President of Research & Development Therapeutics · SCHRODINGER INC

In a September 2020 appearance on NewYorkBIO's Virtual Breakfast series, Karen Akinsanya, then President of Research & Development Therapeutics at Schrodinger, discussed the company's dual identity as both a software and biotech firm. She described Schrodinger's physics-based software as enabling atomistic-level modeling of molecular interactions, allowing researchers to explore chemical space computationally rather than through iterative synthesis. Akinsanya noted that she joined Schrodinger after using its software at Merck, where she saw the potential to apply the tools more broadly across multiple drug targets. Akinsanya highlighted Schrodinger's collaborative structure, describing the company as "completely virtual" with a lab that "extends around the world." She mentioned partnerships with Google Cloud and pharmaceutical companies including Novartis, Gilead, and Takeda to identify antivirals for COVID-19. She contrasted Schrodinger's physics-based methods with typical AI/ML approaches, stating that physics-based simulations can provide accurate compound interactions even when training data is limited. Akinsanya also discussed her passion for science education, noting that she co-founded My Tech Learning to create a lab where children can explore experiments, and expressed a desire to see "science coaches" in every community working with children at the bench.

Profile compiled from Karen Akinsanya's verified public interviews and appearances. See all quotes & transcripts →

More from Karen Akinsanya SCHRODINGER INC (SDGR) Full Transcript Explore All Executives